Clinical Trials
34 trialsNCT06458712 2026-05-27
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
Duke Street Bio Ltd
Phase 1 Recruiting
NCT07326566 2026-05-27
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics, Inc.
Phase 2 Recruiting
NCT07428616 2026-05-27
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
Phase 2 Recruiting
NCT05538130 2026-05-20
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
Phase 1 Recruiting
NCT07569042 2026-05-06
A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
Phase 1/2 Recruiting
NCT06012695 2026-04-29
NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma
Novelwise Pharmaceutical Corporation
Phase 1/2 Recruiting
NCT07297212 2026-04-29
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
NCT05786924 2026-04-21
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Servier
Phase 1/2 Recruiting
NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
NCT07100730 2026-04-16
IPAX BrIGHT
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT06253871 2026-04-13
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
Phase 1 Recruiting
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT06496971 2026-04-09
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients
NaviFUS Corporation
Phase 3 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT05124912 2026-02-20
REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Phase NA Recruiting
NCT04427384 2026-02-13
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
GT Medical Technologies, Inc.
Recruiting
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT03423628 2025-12-22
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
AstraZeneca
Phase 1 Recruiting
NCT06764940 2025-11-28
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07206498 2025-11-28
WAYWIN103
Wayshine Biopharm, Inc.
Phase 1/2 Recruiting
NCT06136884 2025-10-01
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A2A Pharmaceuticals Inc.
Phase 1 Recruiting
NCT06309251 2025-09-03
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
Danone Nutricia SpA Società Benefit
Recruiting
NCT06907043 2025-08-19
EIK1004-001
Eikon Therapeutics
Phase 1/2 Recruiting
NCT06128148 2025-07-14
JYP0322
Guangzhou JOYO Pharma Co., Ltd
Phase 1 Recruiting
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT05460507 2025-03-30
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Plus Therapeutics
Phase 1 Recruiting
NCT01906385 2025-03-26
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Plus Therapeutics
Phase 1/2 Recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT05891002 2024-12-13
Accuracy of Robotically Assisted Cranial Biopsies
Brainlab AG
Recruiting
NCT05948813 2024-11-21
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
TYK Medicines, Inc
Phase 2 Recruiting
NCT04253015 2024-02-07
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
RECORDATI GROUP
Recruiting
NCT05961111 2023-07-27
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Recruiting